Quest Diagnostics financials
$237.62+0.55%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B |
| Gross profit | $1.03B | $942.0M | $910.0M | $949.0M | $943.0M | $863.0M | $858.0M | $811.0M | $804.0M | $771.0M | $736.0M | $754.0M |
| Gross margin | 33.7% | 32.5% | 32.4% | 33.7% | 34.2% | 32.5% | 32.7% | 32.6% | 33.5% | 32.6% | 32.2% | 32.9% |
| Operating income | $459.0M | $401.0M | $369.0M | $409.0M | $438.0M | $348.0M | $355.0M | $331.0M | $355.0M | $300.0M | $267.0M | $342.0M |
| Net income | $319.0M | $252.0M | $245.0M | $243.0M | $281.0M | $220.0M | $220.0M | $225.0M | $228.0M | $194.0M | $192.0M | $223.0M |
| Net margin | 10.5% | 8.7% | 8.7% | 8.6% | 10.2% | 8.3% | 8.4% | 9.0% | 9.5% | 8.2% | 8.4% | 9.7% |
| Diluted EPS | $2.84 | $2.24 | $2.17 | $2.16 | $2.47 | $1.94 | $1.94 | $1.99 | $2.03 | $1.72 | $1.73 | $1.96 |
| EBITDA | $605.0M | $548.0M | $514.0M | $551.0M | $581.0M | $488.0M | $490.0M | $456.0M | $472.0M | $416.0M | $267.0M | $453.0M |
| Operating cash flow | $597.0M | $278.0M | $465.0M | $563.0M | $544.0M | $314.0M | $464.0M | $356.0M | $360.0M | $154.0M | $527.0M | $207.0M |
| Free cash flow | $459.0M | $164.0M | $307.0M | $419.0M | $436.0M | $197.0M | $341.0M | $250.0M | $268.0M | $50.0M | $455.0M | $102.0M |
| Diluted shares | 112.0M | 112.0M | 113.0M | 113.0M | 113.0M | 113.0M | 113.5M | 113.0M | 112.0M | 112.0M | 112.9M | 114.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $626.0M | $393.0M | $420.0M | $432.0M | $319.0M | $188.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $5.64B | $5.66B | $5.67B | $5.67B | $5.67B | $5.86B |
| Total assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B |
| Total liabilities | $9.04B | $8.93B | $8.94B | $8.82B | $8.62B | $8.75B |
| Shareholders' equity | $7.82B | $7.67B | $7.21B | $7.29B | $7.26B | $6.96B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology